Abstract
Introduction
Hyaluronan (HA) is assumed to have a regulatory role in the bone remodelling process by influencing the behaviour of mesenchymal stem cells (MSCs), osteoblasts and osteoclasts. The hyaluronan synthases (HAS1, HAS2 and HAS3) which are responsible for the formation of HA are expressed in human MSCs (hMSCs). Although HAS are only active when they are located in the plasma membrane and an intracellular storage pool of the HAS is assumed, the mechanisms controlling the intracellular traffic of HAS are hardly investigated. Since chitin synthases and cellulose synthases, members of the same enzyme family like the HAS, are regulated by interaction with the cytoskeleton, we hypothesize that HAS interrelate somehow with the cytoskeleton and that their expression, their transport and/or their activity are regulated via mechanotransduction.
Methods and Results
We generated immortalized hMSCs (SCP-1) constitutively expressing eGFP-tagged HAS by lentiviral gene transfer (SCP1-HAS1-eGFP, SCP1-HAS2-eGFP and SCP1-HAS3-eGFP). The expression of the transgene HAS was verified by RT-PCR, western blot, FACS analysis and direct fluorescence microscopy or immunofluorence. The enzymatic activity of the transgene HAS was determined by HA-ELISA and by staining of HA. hMSCs expressing lifeact-RFPruby and HAS-eGFP were investigated in a video timelapse analysis in order to study the putative interaction of HAS-eGFP with the actin cytoskeleton. The HAS-eGFP proteins are globular structured and aligned along the actin filaments. The timelapse pictures show that the HAS-eGFP moves without loss of their alignment to actin. In addition we investigated the impact of shear stress on hMSCs under defined flow conditions. The upregulation of the expression levels of the three HAS isoforms was shown by quantitative real time RT-PCR after exposure to the stimulus.
Discussion
Here, we were able to show the regulation of HAS expression via mechanotransduction. At the moment we investigate if HAS activity and their transport towards the plasma membrane are changed by shear stress. Furthermore we generate hMSCs expressing eGFP tagged HAS in their active form. We have first hints for an interaction of the transgene HAS with the actin cytoskeleton. Our cells can be used for further investigation of the functional and regulatory role of HAS in the bone microenvironment. In some bone diseases such as osteogenesis imperfecta, multiple myeloma and osteoporosis, the HA content in the bone or HAS expression in the hMSCs are changed. Understanding the role of HA in bone regeneration and the regulatory mechanisms of HAS in the hMSCs will provide therapeutic starting points for an improved fracture healing in patients suffering from one of these bone diseases.
